This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Harvard Bioscience (HBIO) Is a Great Choice for "Trend" Investors, Here's Why
by Zacks Equity Research
Harvard Bioscience (HBIO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
4 Breakout Stocks You Must Add Right Away to Your Portfolio
by Nitish Marwah
The logic behind this strategy for stock selection is to identify stocks that are trading within a narrow band.
5 Stocks with Solid Track Records at Attractive Prices
by Sejuti Banerjea
This is probably the time to focus on fundamentals because we don't want to overpay for stocks in a buoyant market.
Surging Earnings Estimates Signal Upside for Harvard Bioscience (HBIO) Stock
by Zacks Equity Research
Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Harvard Bioscience (HBIO) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harvard Bioscience (HBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Harvard Bioscience (HBIO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 66.67% and 6.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -125.00% and -15.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Drab Near-Term Prospects for Scientific Instruments Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is witnessing a slump in demand for instruments as laboratories and research facilities remain closed in the wake of the pandemic predicament.
Harvard Bioscience (HBIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 of the Best Stocks to Buy for a Post-Pandemic Rally
by Tirthankar Chakraborty
The S&P 500 posted solid gains of 20.8%, 18% and 10.4% in the 12-month period after the first occurrence of SARS, MERS and Ebola back in 2003, 2013 and 2014, respectively.
Scientific Instruments Industry Outlook: Prospects Look Good
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is benefiting from solid prospects in emerging markets, robust end-market demand and increasing spending on health care.
Harvard Bioscience Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Harvard Bioscience has been struggling lately, but the selling pressure may be coming to an end soon.
Why Harvard Bioscience (HBIO) Might be Well Poised for a Surge
by Zacks Equity Research
Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Harvard Bioscience (HBIO) Matches Q3 Earnings Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and -3.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) to Report Q3 Results: What Awaits?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) Q2 Earnings Match Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 0.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Harvard Bioscience (HBIO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -33.33% and -0.95%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Q1 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) Q1 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) Meets Q3 Earnings Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 0.75%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Harvard Bioscience has been struggling lately, but the selling pressure may be coming to an end soon.
The Zacks Analyst Blog Highlights: BG, Harvard Bioscience, Vertex Energy, Hallmark and Summer Infant
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BG, Harvard Bioscience, Vertex Energy, Hallmark and Summer Infant